
Join to View Full Profile
Elm and Carlton StCGP L4-318Buffalo, NY 14263
Phone+1 716-845-7739
Dr. Sung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2014 - 2018
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2012 - 2014
- New York University School of MedicineClass of 2012
- Cornell UniversityBA, Biology, Chemistry, Cum Laude with Distinction in All Subjects, 2000 - 2004
Certifications & Licensure
- NY State Medical License 2021 - 2026
- PA State Medical License 2012 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.Sarah J Skuli, A'ishah Bakayoko, Marisa Kruidenier, Bryan Manning, Paige Pammer
Leukemia. 2025-07-09 - Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.Jeffrey Baron, Daniel Appiah, Mark G Faber, Han Yu, Tara Cronin
Leukemia & Lymphoma. 2025-05-01 - Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy.Sawyer Bawek, Matthew Burwinkel, Prutha Patel, Katy Wang, Kristopher Attwood
Leukemia Research. 2025-03-01
Press Mentions
- Ph+ALL: Post-Induction, Ponatinib Yields Molecular ResponseMay 31st, 2025
- Roswell Park Teams Draw More Than $36 Million in Research GrantJanuary 27th, 2022
- Roswell Park Hematologists Present New Research on FLT3 Inhibitors, CART-19 at ASH Annual MeetingDecember 11th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: